Post Reply
2881-2900 of 10899
Somehow I feel that biosensors is being overvalued, my reasonable price for biosensors is ranging from $0.80-$1.00 ...
bishan22 ( Date: 11-Oct-2011 10:08) Posted:
Unload half at 1.245 as market is unstable. Play safe. 
bishan22 ( Date: 04-Oct-2011 10:44) Posted:
| Jumped in at 1.125. Good luck. |
|
|
|
Biosensors going to see good numbers this quarter due to Japan licensing revenue growth. J& J has pullout the stent buisness which left Terumo having to cope with high demand for biomatrix...
trade as intra or day trade?
On Friday, Biosensors re-test the resistance at $1.22 and closed at $1.21 with HIGH volume of 5.01 million shares traded.
A
white candle sticks with long upper shadow similar to “shooting star”
affirms that investors are fearful on the resistance at $1.22.
RSI & MACD are bullish as RSI trend upwards.
Important Resistance of Biosensors: $1.22
Immediate Support of Biosensors: $1.19
Currently prices are resisted by 20/200 days MA at $1.22
For
the past 2 sessions,........................ READ MORE
DJ MARKET TALK: DBSV Upgrades Biosensors To Buy From Hold
0912 GMT [Dow Jones] STOCK CALL: DBS Vickers upgrades Biosensors (B20.SG) to Buy from Hold and raises its target to S$1.71 from S$1.40. It says news Biosensors has completed the acquisition of the remaining 50% stake in its JWMS joint venture, " is a plus" as BIG now gets to consolidate JWMS' financials and is also well positioned to benefit if BioMatrix Flex is approved for sale in China, which it says will be a longer-term catalyst for BIG " hypothetically, a 5% market share could add another 8% to FY12F's revenue of US$312 million." The house is also optimistic on the licensing sales from Terumo in Japan and expects licensing sales growth of close to 5X to over US$80 million in FY12F " we believe further growth opportunities exist as Terumo is still only in its initial stages of marketing the NOBORI stent in Japan." DBSV raises its FY12/13F earnings estimates by 56%/34% after taking into account consolidation of JWMS and strong licensing revenue outlook. Shares close +4.9% at S$1.19. (matthew.allen@dowjones.com)
Biosensors International Group: BUY (Upgrade from Hold) S$1.125 Bloomberg:
BIG SP
More positives from JWMS
Price Target : 12-Month S$ 1.71 (Prev S$ 1.40)
By: Alfie YEO +65 6398 7957 / Andy SIM +65 63987969
· Acquisition of an additional 50% in JWMS is positive for earnings
· Expect licensing revenue to be strong
· FY12/13F earnings raised by 56%/34%
· China catalyst still to come. Upgrade to Buy, TP raised to S$1.71
Positive on BIG’s prospects. BIG has completed the acquisition of the
remaining 50% stake in joint venture company, JWMS. We believe its outlook
will be rosier on the back of : (i) higher earnings contribution from JWMS
(ii) sustained strong licensing revenue from Terumo and (iii) longer term
catalysts from the approval of BioMatrix Flex for the China market.
50% acquisition of JWMS is a plus. BIG now gets to consolidate JWMS’
financials. BIG is also now well positioned to take advantage in the event
BioMatrix Flex is approved for sale in China.
Robust growth from licensing revenue. We remain optimistic on the licensing
sales from Terumo in Japan and expect licensing sales growth of close to
five times to over US$80m in FY12F. We believe further growth opportunities
exist as Terumo is still only in its initial stages of marketing the NOBORI
stent in Japan.
Catalyst still to come. BioMatrix Flex’s approval for sale in China will be
a longer term catalyst for BIG. Hypothetically, a 5% market share could add
another 8% to FY12F’s revenue of US$312m.
Upgrade to Buy, SOTP-based TP S$1.71. We have raised FY12/13F earnings by
56%/34% after taking into account consolidation of JWMS and strong
licensing revenue outlook. We SOTP valuation of BIG at S$1.71 translates to
16x forward earnings, equivalent to peers and -0.5 standard deviation PE.
Upgrade to Buy with 52% potential upside.
Nomura
Stronger balance sheet and growth profile
Entering a new phase of growth
Action: Reiterating Buy following completion of JWMS deal
Following the JW Medical Systems (JWMS) transaction, Biosensors is
now well positioned with earnings underpinned by growth in Japan, China
and Europe. The group’s balance sheet has improved significantly with
shareholders’ funds expanding to USD1bn and cash rising to more than
USD200mn. We reiterate Buy, as we project strong momentum in
earnings growth over the next couple of years.
Catalyst: Growing market share and strong boost from Japan
Strong contribution from Japan and global market-share gains should
sustain a stock rerating. Biosensors is benefiting from the withdrawal of
J& J and market acceptance of its bifurcated stent.
Strong clinical trial data to support
Strong clinical trial data achieved for its flagship Biomatrix stent and
BioFreedom, its next generation stent, should reinforce the growth
prospects for the group. Updated trial data to be announced at year end
may be another rerating driver.
Enhanced balanced sheet provide opportunity to grow
We see Biosensors potentially pursuing M& A to entrench its market
position and expand into higher-margin product adjacencies to position for
the next phase of its growth.
Valuation: Attractively priced relative to valuation of SGD1.65
Our SOTP-based TP of SGD1.65 has 35% implied upside, supported by
11.1x FY13F P/E on an EPS growth of 38.0% over FY12F- FY13.
Biosensors International Group, Ltd. and Shandong
Weigao Group Medical Polymer Company Limited (“Shandong Weigao”)
announced the restructuring of the shareholding in JW Medical Systems
Ltd (“JWMS”) whereby Biosensors acquired the remaining 50% equity
interest in JWMS from Shandong Weigao.
http://sgsharemarket.com/home/2011/10/singapore-company-highlights-04102011/?=Biosensors
Today may be a good entry for this bugger. Good luck.
iPunter ( Date: 23-Sep-2011 09:00) Posted:
1.19 may be a good bet... but may need to wait a few days...
|
|
Biosensors International Group: Completes acquisition of remaining 50% stake in JWMS
Summary: Biosensors International Group (BIG) announced that it has completed its acquisition of the remaining 50% stake in JW Medical Systems (JWMS) from Shandong Weigao Group Medical Polymer (Shandong Weigao). As a result, Shandong Weigao has received (i) a cash payment of S$160m (ii) 260m new ordinary shares, making it a key shareholder of BIG and (iii) US$120m principal amount of 4% convertible notes due 2014. We believe that BIG would now be able to concentrate on increasing its penetration into the Chinese DES market given JWMS’s strong positioning there. The group would also be able to leverage on Shandong Weigao’s experience in China. We had already incorporated this acquisition in our assumptions and consolidated JWMS’s numbers in our estimates from 3QFY12 onwards. As such we retain our forecasts and fair value estimate of S$1.68. Given an attractive upside potential of 45.4% from current price level, we reiterate our BUY rating on the stock.
A N N O U N C E M E N T
BIOSENSORS INTERNATIONAL GROUP, LTD.
(Incorporated in Bermuda as an exempted company limited by shares)
(Company Registration Number: EC 24983)
RESOLUTIONS PASSED AT THE SPECIAL GENERAL MEETING OF THE COMPANY
IN CONNECTION WITH THE PROPOSED ACQUISITION OF THE REMAINING 50%
EFFECTIVE INTEREST IN JW MEDICAL SYSTEMS LIMITED
The Board of Directors of Biosensors International Group, Ltd. (the “
announce that at the Special General Meeting of the Company held on 28 September 2011, all
resolutions relating to the matters set out in the Notice of Special General Meeting dated 13
September 2011 were duly passed.
Company”) is pleased to
Biosensors International (BIG SP, $1.19, BUY, TP $1.49) – We initiate coverage on Biosensors International with a BUY rating and a SOTP-based target price of $1.49, implying 25% upside. The company has progressed from a high-risk start-up to one poised for high growth. With BioMatrixTM, the world’s first commercially available biodegradable drug-eluting stent, to spur its growth, we expect EPS to multiply at 63% CAGR over FY Mar12-14. Approval of the product by China’s State Food and Drug Administration would add a new impetus to the share price.
Event
We initiate coverage on Biosensors International with a BUY rating and a SOTP-based target price of $1.49, implying 25% upside. The company has progressed from a high-risk start-up to one poised for high growth. With BioMatrixTM, the world’s first commercially available biodegradable drug-eluting stent, to spur its growth, we expect EPS to multiply at 63% CAGR over FY Mar12-14. Approval of the product by China’s State Food and Drug Administration would add a new impetus to the share price.
Our View
BioMatrixTM is the first biodegradable drug-eluting stent (DES) of its kind to be commercially available in the world. Backed by 10 years of R& D efforts and three years of positive clinical trial data, it is slated to lift Biosensors to a higher plane as the company gains market share in key regions worldwide.
With the acquisition of the remainder 50% stake in JW Medical Systems (JWMS), Biosensors stands to benefit fully from the former’s high-growth DES business in China. More importantly, it can now tap on JWMS’s strong distribution network to market its BioMatrixTM DES. JWMS accounted for almost one-quarter of the market share of China’s medical device market in 2009. With the full acquisition, Biosensors can expect JWMS to contribute about one-third of its net profit in FY Mar13.
Terumo Corporation of Japan licenses the BioMatrixTM technology from Biosensors and produces its version of the DES under the Nobori brand. In return, it pays a royalty to Biosensors. Terumo claimed to have won 30% of the Japanese market share two months after the product launch. We expect licensing fees to quadruple from US$17m in FY Mar11 to US$66m in FY Mar12 and to grow strongly until the licensing agreement expires in 2016.
Action & Recommendation
Biosensors is a growth stock in the defensive healthcare sector. It has outperformed vis-ŕ-vis the STI, falling only 12.8% since 1 August 2011 compared to the 17.3% decline in the index. Based on its price-to-sales ratio, the stock is trading at a lower valuation than when there were more uncertainties. We expect EPS to grow by 90% in FY Mar12 and 42% in FY Mar13. Our SOTP-based target price of $1.49 implies FY Mar12 PER of 18.7x and FY Mar13 PER of 11.0x. Initiate with BUY.
|
*DJ Biosensors International Group Started
At Buy With S$1.49 Target By Kim Eng (2011/09/27 09:10AM)
Anyone have the details? |
1.19 may be a good bet... but may need to wait a few days...
Strong support at 1.25. Today may test again. Good luck.
[Dow Jones] Kim Eng says Singapore's healthcare sector would be a good place to look for oversold and undervalued stocks, as uncertainties surrounding the European debt crisis reverberate through the equity market, and stocks get sold down " as a result of herd instinct without regard to their fundamentals." It says " it's not rocket science to figure out" that healthcare is a defensive sector, as " even in a recession, it would be hard to put off spending on healthcare needs." It adds, healthcare stocks have garnered premium valuations due to several M& A deals which were done at P/Es of 23X-32X " this would diminish the risk of a severe de-rating in the sector." Kim Eng notes Raffles Medical Group (R01.SG) demonstrated strong resilience in the last financial crisis, while a study of healthcare stocks since Aug. 1 sell-off shows that most have outperformed the STI, with Biosensors (B20.SG) in particular, down only 5.5% vs the STI's 14.1% drop. RMG is off 0.5% at S$2.15, BIG is off 0.8% at S$1.285. (
matthew.allen@dowjones.com)
Biosensors Int'l Group 1.245 -0.030 -2.35%  Discuss » |
Business: Co produces medical devices for intervent'l cardiology & critical care procedures. [1Q12 Turnover] Interventional cardiology (66.1%), licensing (27.4%), critical care (6.5%).
Insight: Sep-11, Co has been given the approval from SGX on the issuance of consideration & conversion shrs for the acqn of the remaining 50% interest in JW Medical Systems. Mar-11, SGX-ST has granted Co's proposed placement of 216.3m |
 |
 S$1.245 |
-0.030 -2.35% |
Buy: 1.245 |
52-Wk Chg: +0.245 +24.50% |
| Vol: 4,775 |
Sell: 1.250 |
1-Mth Chg: -0.045 -3.49% |
| 22-09-11 17:05:05 |
|
|
|
| Open : |
1.265 |
No. of Shares : |
1,342.267m |
PE : |
31.5 |
| High : |
1.265 |
Mkt Cap : |
S$1,671.122m |
EPS : |
US$0.032 |
| Low : |
1.240 |
52-Wk High : |
1.410 |
Last 12m Div : |
-- |
| Last Close : |
1.275 |
52-Wk Low : |
0.960 |
Yield : |
-- |
| Price-to-Book : |
3.40 |
Avg. Vol : |
8,661 |
NAV : |
S$0.3662 |
| ▼ Biosensors Int'l Group 1.245 -0.030 -2.35% Discuss » |
Business: Co produces medical devices for intervent'l cardiology & critical care procedures. [1Q12 Turnover] Interventional cardiology (66.1%), licensing (27.4%), critical care (6.5%).
Insight: Sep-11, Co has been given the approval from SGX on the issuance of consideration & conversion shrs for the acqn of the remaining 50% interest in JW Medical Systems. Mar-11, SGX-ST has granted Co's proposed placement of 216.3m new... Read More |
| ▼ Biosensors Int'l Group 1.245 -0.030 -2.35% Discuss » |
Business: Co produces medical devices for intervent'l cardiology & critical care procedures. [1Q12 Turnover] Interventional cardiology (66.1%), licensing (27.4%), critical care (6.5%).
Insight: Sep-11, Co has been given the approval from SGX on the issuance of consideration & conversion shrs for the acqn of the remaining 50% interest in JW Medical Systems. Mar-11, SGX-ST has granted Co's proposed placement of 216.3m new... Read More |
| Biosensors Int'l Group 1.245 -0.030 -2.35% Discuss » |
Business: Co produces medical devices for intervent'l cardiology & critical care procedures. [1Q12 Turnover] Interventional cardiology (66.1%), licensing (27.4%), critical care (6.5%).
Insight: Sep-11, Co has been given the approval from SGX on the issuance of consideration & conversion shrs for the acqn of the remaining 50% interest in JW Medical Systems. Mar-11, SGX-ST has granted Co's proposed placement of 216.3m |
to acquire the remaining 50% interest in JW Medical Systems
Limited (“JWMS”) from Shandong Weigao Group Medical Polymer Company Limited
which is hold in Treasure Solutions .
